DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville, MD 20857

ANDA 77-960 October 13, 2006

Vintage Pharmaceuticals, LLC
Attention: Sam E. Kleiner
Manager, Regulatory Affairs
120 Vintage Drive
Huntsville, AL 35811

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated October 31, 2005, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Valproic Acid Syrup (Valproic Acid Oral Solution, USP), 250 mg/5 mL.

Reference is also made to your amendments dated March 30, June 28, and August 10, 2006.

We have completed the review of this ANDA and have concluded that adequate information has been submitted to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Valproic Acid Syrup, 250 mg/5 mL, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Depakene Syrup, 250 mg/5 mL, of Abbott Laboratories.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

cc: ANDA 77-960
Division File
Field Copy
HFD-013
HFD-610/Orange Book Staff

Approved Electronic Labeling Located at:

\\Cdsesub1\n77960\N_000\2006-08-10\Labeling\Valproic Acid 4 oz.pdf
\\Cdsesub1\n77960\N_000\2006-08-10\Labeling\Valproic Acid 8 oz.pdf
\\Cdsesub1\n77960\N_000\2006-08-10\Labeling\Valproic Acid Pint.pdf
\\Cdsesub1\n77960\N_000\2006-06-28\Valproic Acid\Insert\8181939 R6-06 R99A Valp pr2.pdf

Endorsements:
HFD-/L.Hussain/10/12/06
HFD-625/S.Liu/10/12/06
HFD-617/L.Kwok/10/12/06
HFD-613/M.Shin/
HFD-613/L.Golson/10/10/06 via email
V:\Chemistry Division III\Team 11\PM Folder\77960.ap.DOC

APPROVAL